{"id":"W2810970248","doi":"10.3324/haematol.2017.185991","title":"A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma","year":2018,"lang":"en","type":"article","venue":"Haematologica","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia","funders":"Takeda Oncology","keywords":"Ixazomib; Medicine; Melphalan; Prednisone; Multiple myeloma; Maintenance therapy; Internal medicine; Adverse effect; Surgery; Lenalidomide; Chemotherapy; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001631314,0.001320538,0.001919999,0.0005264129,0.0004459207,0.0006266551,0.0008435582,0.0007960651,0.001727384],"category_scores_gemma":[0.0008187812,0.0006310007,0.001042246,0.0004227413,0.0008527734,0.0006000232,0.0003292029,0.003371244,0.0003589754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008206403,"about_ca_system_score_gemma":0.001589689,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006686628,"about_ca_topic_score_gemma":0.001922319,"domain_scores_codex":[0.9995317,0.0002045126,0.00003001842,0.00008654985,0.00005284853,0.00009426067],"domain_scores_gemma":[0.9992117,0.0001122855,0.0001803471,0.00008340798,0.00003866753,0.0003735563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5217544,0.2384773,0.009694832,0.0008078249,0.001066839,0.0004745463,0.0005735629,0.004385604,0.1124377,0.0003781274,0.001844645,0.1081048],"study_design_scores_gemma":[0.2693664,0.7167722,0.007285528,0.00002025152,0.0002288407,0.0001722104,0.00003780251,0.0009155226,0.004092021,0.0001147875,0.0009725377,0.00002192654],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964379,0.0005652498,0.0004052312,0.0001515525,0.00004820062,0.001628703,0.0002171045,0.00003453344,0.0005114585],"genre_scores_gemma":[0.9920253,0.001109603,0.002313746,0.0005346914,0.0001223051,0.001795872,0.000754586,0.00001532456,0.001328594],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001919999,"threshold_uncertainty_score":0.008627355,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08065535250103235,"score_gpt":0.3476845975581068,"score_spread":0.2670292450570745,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}